{'fraction_non_alphanumeric': 0.033863165169315826, 'fraction_numerical': 0.011748445058742226, 'mean_word_length': 5.552036199095022, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identification of Potent Inhibitors for Resistant Form of Chronic Myelogenous Leukaemia (CML)

The BCR-ABL protein is the causative agent in the pathogenesis of chronic myeloid leukemia (CML). Although there are several drugs in the market which inhibit BCR-ABL efficiently there are some cases of resistance1. Imatinib2,3, nilotinib3,4, bosutinib4 ,dasatinib5, bafetinib6 are approved tyro- sine kinase inhibitors (TKI's) and more recently, ponatinib was approved TKI which is shown to bind and inhibit the imatinib resistant BCR-ABL (T315I mu- tant). Ponatinib showed greater side effects like cardiovascular, cerebrovascular and peripheral vascular thrombosis, including fatal myocardial infarction and stroke7. Therefore, there is a need to identify new TKI's which have greater in- hibition capacity than marketed TKI's with lesser side effects. In this current study, we have selected mutant BCR-ABL (T315I mutant) as a target protein which constitutes 20% of all mutations and screened several small molecule li- braries to investigate the potential drug like compound against the BCR-ABL. Potential drug candidates were further examined for their druggability, stability and binding efficacy using computational approaches. Our investigation showed a group of select lead compounds exhibits promising binding affinity than the existing drugs such as ponatinib, imatinib, dasatinib, nilotinib, bosutinib, bafet- inib that may be considered.